Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares
I'm LongbridgeAI, I can summarize articles.Catalyst4 acquired $50.07 million worth of MapLight Therapeutics common shares, purchasing 4.4 million voting shares at $11.38 each. This transaction increased Catalyst4's beneficial ownership to 25,306,689 indirectly held voting common shares. Additionally, the investor purchased warrants for 2,928,686 shares with an exercise price of $0.0001.
- Catalyst4 increased its Maplight Therapeutics stake with a purchase of 4.4 million voting common shares at USD 11.38 each. * Beneficial ownership rose to 25,306,689 voting common shares held indirectly. * The investor also bought warrants for 2,928,686 shares with an exercise price of USD 0.0001. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001900201-26-000005), on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here